<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01679340</url>
  </required_header>
  <id_info>
    <org_study_id>SOXSP</org_study_id>
    <nct_id>NCT01679340</nct_id>
  </id_info>
  <brief_title>A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery</brief_title>
  <official_title>Phase Ⅱ Study of S-1 Combined With Oxaliplatin (SOX)Verse S-1 Combined With Cisplatin(SP) in Adjuvant Chemotherapy After D2 Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taiho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficiency and safety of SOX or SP adjuvant chemotherapy to phase II and
      III gastric cancer patients after D2 surgery. If SOX is equal to SP in efficiency and less
      toxicity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>replase free survival</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>S-1+oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d oxaliplatin: 65mg/m2, D1,D8, 3weeks/cycle after 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-1+cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d) cisplatin: 75mg/m2, D1, every 3 weeks After 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>Mode of administration: orally (capsules) Dosing schedule:80mg/m2, Bid,D1-14,every 3 week,for 8-10cycles</description>
    <arm_group_label>S-1+oxaliplatin</arm_group_label>
    <arm_group_label>S-1+cisplatin</arm_group_label>
    <other_name>TS-1</other_name>
    <other_name>Aisiwan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Mode of administration: intravenously Doseing schedule: 65 mg/m2 D1,D8,every 3 week, for 6 cycles</description>
    <arm_group_label>S-1+oxaliplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Mode of administration: intravenously Dosing schedule: 75mg/m2 D1,every 3 week,for 6 cycle</description>
    <arm_group_label>S-1+cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed Phase III adenocarcinoma of gastric and esophageal-gastric
             junction ( AJCC 7th)

          -  without previous treatment, including radiotherapy, chemotherapy and immunotherapy

          -  Hb≥90g/L,WBC 4×109/L-10×109/L,ANC≥2×109/L,Platelet≥100×109/L

          -  creatinine≤1 UNL

          -  total bilirubin≤1.5 UNL,AST(SGOT),ALT(SGPT) and ALP≤2.5 UNL

          -  ECOG score 0 - 2

          -  take chemotherapy for 8 weeks after surgery

          -  older than 18 years

          -  can be followed up, good compliance

          -  can take medicine orally

          -  having signed informed consent

        Exclusion Criteria:

          -  combined disease lead to Life Expectancy less than 3 years

          -  any evidence to show metastasis,including cancer cells in peritoneal fluid

          -  inability to take oral medication for difficult to swallow, intestinal
             obstruction，active intestinal blooding or perforation

          -  previous treatment,including cytotoxic chemotherapy, radio chemotherapy or
             immunotherapy ( except corticosteroid hormone）

          -  operation within 4 weeks, or not recovered from last major operation

          -  allergy with fluorouracil

          -  allergy with Platinum or any composition in research drugs

          -  uncontrollable seizure disorder，central nervous system disease or mental disorders,
             and has clinical significance by judgement of researchers, or can influnce
             understanding of informed consent or compliance to take orally drugs

          -  in the past 12 months, has clinical significant heart disease(active),such as
             symptomatic coronary heart disease, &gt; =Stage II congestive cardiac failure;congestive
             heart failure as NYHA standard, or serious arrhythmias need take medicine( as Appendix
             10th),or myocardical infarction.

          -  pregnancy， lactation， women in child-bearing period and her spouses reject to take
             effictive method to conraception

          -  other previous malignancy within 5 years, except healed skin basal cell carcinoma and
             carcinoma in cervix

          -  peripheral neuropathy&gt; grade 1 of CTCAEv3, except the neural abnormality patients who
             only lose deep tendon reflex（DTRs）.

          -  serious complicated infection or other complicated diseases and hard to controll.

          -  As one of belowing:

          -  ANC &lt; 2×109/L

          -  Platelet&lt;100×109/L

          -  total bilirubin&gt;1.5 UNL

          -  ALAT、ASAT &gt; 2.5 x ULN

          -  ALP&gt; 2.5 x ULN

          -  Any investigational agent within the past 28 days. That is the patient had jioned
             another trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shen Lin, professor</last_name>
    <phone>010-88196561</phone>
    <email>xiaotong10241@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shen Lin, Professor</last_name>
      <phone>010-88196561</phone>
      <email>xiaotong10241@sina.com</email>
    </contact>
    <investigator>
      <last_name>Shen Lin, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>September 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2012</study_first_posted>
  <last_update_submitted>May 17, 2015</last_update_submitted>
  <last_update_submitted_qc>May 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>Director of GI oncology</investigator_title>
  </responsible_party>
  <keyword>Gastric cancer</keyword>
  <keyword>D2 surgery</keyword>
  <keyword>S-1</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

